| |
Intervention group
|
Placebo group
|
Difference intervention group (absolute value and %)
|
Difference placebo group (absolute value and %)
|
95% CI of difference
|
p-value
|
|---|
|
Baseline intervention
|
Baseline intervention
|
|---|
|
LDL (SD) mg/dL
|
164.3 (32.2)
|
122.6 (19.8)
|
170.7 (40.9)
|
171.5 (41.8)
|
−41.7 (−23.7%) (28.3)
|
0.8 (0.5%) (24.3)
|
25.9; 56.0
|
<0.001
|
|
total CHOL (SD) mg/dL
|
247.5 (38.1)
|
204.0 (26.0)
|
251.2 (39.2)
|
255.1 (50.0)
|
−43.5 (−16.5%) (31.1)
|
4.0 (2.0%) (23.7)
|
31.6; 63.3
|
<0.001
|
|
HDL (SD) mg/dL
|
56.3 (14.3)
|
58.0 (13.8)
|
53.5 (13.9)
|
54.3 (14.0)
|
1.6 (3.5%) (4.3)
|
0.8 (2.4%) (7.7)
|
−4.3; 2.7
|
0.64
|
|
TG (SD) mg/dL
|
134.5 (57.9)
|
117.5 (53.9)
|
132.7 (49.5)
|
150.3 (84.4)
|
−16.1 (−8.7%) (37.4)
|
19.3 (15.9%) (64.6)
|
5.7; 65.1
|
0.02
|
|
apoA (SD) mg/dL
|
162.2 (39.5)
|
171.2 (5.8)
|
157.3 (30.6)
|
161.1 (31.0)
|
4.7 (2.9%) (9.4)
|
3.9 (3.1%) (18.8)
|
−18.5; 8.2
|
0.44
|
|
apoB (SD) mg/dL
|
115.5 (25.1)
|
96.6 (16.5)
|
119.3 (22.1)
|
126.3 (5.4)
|
−19.0 (−14.7%) (18.3)
|
7.0 (6.0%) (14.1)
|
16.6; 35.5
|
<0.001
|
|
HbA1c (SD) mmol/mol
|
35.3 (3.2)
|
36.1 (2.6)
|
35.9 (6.4)
|
36.7 (6.5)
|
0.9 (2.9%) (1.6)
|
0.7 (2.0%) (1.6)
|
−0.7; 1.1
|
0.61
|
|
oxLDL (SD) U/L
|
80.8 (34.5)
|
61.5 (21.4)
|
69.1 (17.7)
|
72.8 (22.2)
|
−19.4 (−20.4%) (21.7)
|
3.7 (5.2%) (11.3)
|
−35.2; −15.8
|
<0.001
|
- Values in italics are statistically significant.
